Zobrazeno 1 - 10
of 64
pro vyhledávání: ''
Autor:
Shogo Teraoka, Atsushi Takenaka, Katsuya Hikita, Masashi Honda, Hideto Iwamoto, Shuichi Morizane, Bunya Kawamoto, Noriya Yamaguchi, Tetsuya Yumioka, Ryutaro Shimizu
Publikováno v:
Anticancer Research. 41:5767-5773
BACKGROUND This study aimed to investigate the response to platinum-based chemotherapy rechallenge in patients with pembrolizumab-refractory urothelial carcinoma. PATIENTS AND METHODS We retrospectively reviewed 14 patients with pembrolizumab-refract
Publikováno v:
Anticancer Research. 41:5729-5737
Background/aim This study aimed to identify the predictive markers for carboplatin-induced severe thrombocytopenia. Patients and methods We conducted a retrospective cohort analysis of inpatients who received carboplatin and pemetrexed. Results Among
Publikováno v:
Anticancer Research. 41:3543-3560
BACKGROUND/AIM There is a lack of data concerning the surgical treatment of locally advanced squamous cell carcinoma of the uterine cervix (LACC) with neoadjuvant and adjuvant chemotherapy (NACT, ACT) as well as total mesometrial resection (TMMR). Th
Publikováno v:
Anticancer Research. 41:3091-3097
Background/aim The efficacy of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) or aflibercept (F-AFL) as a second-line treatment in metastatic colorectal cancer (mCRC) is established. In this study, the risks and benefit
Autor:
Magda Barinova, Jana Skrickova, P. Opálka, Miloš Pešek, M. Černovská, Martin Safanda, Karolina Hurdalkova, Helena Coupkova, Martin Svaton, Daniel Krejci, Milada Zemanova, Monika Bratová, Michal Hrnčiarik, Daniel Dolezal, J. Krejčí, Petra Zemanova, Leona Koubková, Juraj Kultan, Ondrej Fischer
Publikováno v:
Anticancer Research. 41:2597-2603
Background/aim Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare
Autor:
Roberta Grande, Federica Zoratto, Mario Giovanni Chilelli, Isabella Sperduti, Salvatore De Marco, Maria Grazia Morandi, R. Saltarelli, Carlo Signorelli, Anna Ceribelli, Donatello Gemma, Enzo Maria Ruggeri, Gian Paolo Spinelli
Publikováno v:
Anticancer Research. 41:2553-2561
Background/aim Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have have been shown to improve overall survival in patients with refractory metastatic colorectal cancer. The aim of our study was to evaluate the efficacy and safety profiles of
Autor:
Cameron L. Colgate, Michele T. Yip-Schneider, Eugene P. Ceppa, Molly Kilbane, Nicholas J. Zyromski, Danielle K. DePeralta, Kristen Kelley, C. Max Schmidt, Mazhar Soufi, Christian M. Schmidt, Atilla Nakeeb, Katelyn F. Flick, William A. Wooden, Rachel E. Simpson, Michael G. House
Publikováno v:
Anticancer Research. 41:1895-1901
BACKGROUND/AIM We created a novel, preoperative wellness program (WP) that promotes recovery. This study assessed its impact on patient outcomes after pancreatectomy. PATIENTS AND METHODS Pancreatoduodenectomies (PD) and distal pancreatectomies (DP)
Autor:
Kenichi Yoshimura, Hiroshige Yoshioka, Yuichi Sakamori, Toyohiro Hirai, Hiroaki Nakagawa, Toshihiko Kaneda, Hironori Yoshida, Masataka Hirabayashi, Hiroki Nagai, Asuka Okada, Keisuke Tomii, Hiroaki Ozasa, Young Hak Kim
Publikováno v:
Anticancer Research. 40:2981-2987
Background/aim Continuation maintenance therapy is standard for advanced nonsquamous non-small cell lung cancer; however, the optimal maintenance strategy has yet to be determined. Patients and methods Patients without disease progression after four
Publikováno v:
Anticancer Research. 40:1605-1611
BACKGROUND/AIM The aim of this study was to clarify the risk benefits of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) as third-line and later-line treatment for metastatic colorectal cancer (mCRC). PATIENTS AND METHOD
Autor:
Junji Yonese, Masahiro Ogawa, Iwao Fukui, Toru Inoue, Hitoshi Masuda, Noboru Numao, Takeshi Yuasa, Shinya Yamamoto
Publikováno v:
Anticancer Research. 40:1613-1618
Background/aim To evaluate the efficacy and toxicity of paclitaxel, gemcitabine, and cisplatin (TGP) as second-line treatment for advanced urothelial carcinoma (UC). Patients and methods This study comprised advanced UC progressed after first-line ci